Papers
8
Total Citations
153
H-Index
5
About
Yao Fu is a leading urologic oncologist whose research focuses on advancing surgical and diagnostic strategies for prostate and renal cancers. Dr. Fu’s major contributions center on optimizing preoperative imaging and refining surgical techniques to improve oncologic and functional outcomes. Notably, their highly cited 2017 study (96 citations) demonstrated the superiority of 68Ga-PSMA-11 PET-CT over multiparametric MRI for lymph node staging in intermediate- to high-risk prostate cancer, establishing a new standard for preoperative assessment. Dr. Fu has also pioneered work on Retzius-sparing robot-assisted radical prostatectomy (RS-RARP), showing that tumor location on preoperative MRI independently predicts positive surgical margins, and that a modified RS-RARP approach can reduce margin rates for anterior tumors. Their recent randomized controlled trial (2023) comparing robot-assisted simple enucleation versus standard partial nephrectomy for T1 renal tumors provides high-level evidence for nephron-sparing surgery. Additionally, Dr. Fu has integrated machine learning models to predict pathological upgrade from prostate biopsy to final pathology, and is investigating neoadjuvant darolutamide for high-risk localized prostate cancer. With over 150 total citations and ongoing clinical trials, Dr. Fu’s work directly shapes surgical decision-making and improves patient outcomes in urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8